RIKEN GENESIS

About RIKEN GENESIS

RIKEN GENESIS Co., Ltd. operates as a pivotal player in the field of genomic medicine, stemming from one of Japan's most prestigious research institutions. The company was established on October 15, 2007, as a joint venture between Toppan Printing and RIKEN Venture Capital. This initiative was designed to commercialize the advanced research outcomes of the RIKEN institute, particularly its high-sensitivity genetic analysis and SNP (Single Nucleotide Polymorphism) typing technologies, with the overarching goal of realizing personalized medicine.

The firm was designated a "RIKEN Venture" shortly after its founding, a certification that underscores its role in disseminating RIKEN's research成果 for societal benefit. A significant milestone occurred in June 2016 when Sysmex Corporation, a global leader in clinical laboratory systemization, acquired a majority stake, making RIKEN GENESIS a subsidiary. This strategic integration was aimed at accelerating the practical application of genomic medicine by combining RIKEN GENESIS's expertise in genetic analysis with Sysmex's capabilities in diagnostics and systemization. The company has achieved numerous certifications, including being the first in Japan to receive CLIA certification in 2015, a U.S. quality standard for clinical laboratories, highlighting its commitment to providing highly reliable testing on a global scale.

RIKEN GENESIS's business model is centered on providing a comprehensive suite of genetic analysis services and products. The company's revenue is generated through five main business pillars: clinical sequencing, pharmaceutical development support, contract genetic analysis, reagents and diagnostic products, and Bridged Nucleic Acid (BNA) technology. Clients include medical institutions, research organizations, and pharmaceutical companies globally. For its clinical sequencing business, the company collaborates with medical institutions to analyze genetic variations related to diseases, aiding in diagnostics and treatment selection. In pharmaceutical development, it offers a one-stop service from biomarker measurement to the development and manufacturing of in-vitro diagnostics, including companion diagnostics. The contract analysis service leverages state-of-the-art equipment like next-generation sequencers (NGS) to perform a wide range of analyses, from whole-genome sequencing to targeted sequencing for cancer research. Furthermore, the company develops and sells reagents and diagnostic kits and is involved in the manufacturing and licensing of BNA, a proprietary artificial nucleic acid technology used in drug discovery and diagnostics.